Approval from Health Canada to expand Serenta Registrational Phase 3 trial in FAP and Update on Serenta Progress
Biodexa received Health Canada approval to expand its Phase 3 Serenta trial into Canada, adding three to four new clinical sites to the existing 29 active centers in the US and Europe. Enrollment has accelerated to 73 patients out of a target of 168, supported by a $20 million grant from the Cancer Prevention and Research Institute of Texas.
Key figures
- Drug Name
- eRapa
- Phase Of Trial
- Phase 3
- Centers active
- 29
- Patients target
- 168
- Grant amount usd
- 20000000
- Patients enrolled
- 73
- Centers new canada
- 3 or 4
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.